RMGP Biopharma Investment Fund
8
2M
8
- Areas of investment
Summary
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 6 partakers. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, RM Global Partners, Quark Venture.
The overall number of key employees were 1.
Among the most popular fund investment industries, there is Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Pi Therapeutics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Investments by industry
- Biotechnology (8)
- Therapeutics (4)
- Biopharma (4)
- Life Science (3)
- Health Care (1) Show 2 more
- Investments by region
-
- Israel (7)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 4
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Skip Therapeutics | 01 May 2021 | Biotechnology, Life Science, Biopharma | Seed | HaMerkaz, Ness Ziona, Israel |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.